News

Outsourcing bioconjugation and antibody labelling can help life science and diagnostic organisations access specialist expertise, improve efficiency, reduce costs, and accelerate product development.

This article explains why organisations outsource immunoassay and ELISA development to gain specialist expertise, improve efficiency, reduce costs, and accelerate product development.

Fleet Bioprocessing Ltd. will be going to the London Biotechnology Show , to be held at Olympia on 8th - 9th May 2024. We'd love to talk to you if you're attending, please let us know via our website enquiry form if you'd like to meet up: https://www.fleetbioprocessing.co.uk/contact-us You can read more about the show here: https://londonbiotechshow.com/

Introduction: In the realm of medical devices, particularly in vitro diagnostics (IVD), ensuring the highest standards of quality, safety, and efficacy is paramount. This is where ISO 13485, a globally recognised quality management standard for medical devices, plays a pivotal role. In this article, we will delve into the significance of ISO 13485 accreditation for in vitro diagnostic development and how it contributes to the overall success and reliability of these crucial h

Fleet Bioprocessing will be closed for the week beginning 25th December 2023, re-opening on Tuesday 2nd January 2024. We wish all our clients and partners a very merry Christmas and New Year, and we look forward to working with you in 2024.

Recently, one of Fleet Bioprocessing’s experts was asked to consult on a project. Nothing unusual about that, Fleet experts regularly act as consultants for clients advising on bioconjugation , ELISA and assay development . Where this project differed was that the consultant was asked to provide expert witness testimony in an intellectual property dispute, culminating with taking the witness stand for cross examination in the High Court. Whilst quite different from our usual